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HIV RepoRts
Background: Data on the epidemiology of viral-associated acute lower 
respiratory tract infection (LRTI) from high HIV prevalence settings are 
limited. We aimed to describe LRTI hospitalizations among South African 
children aged <5 years.
Methods: We prospectively enrolled hospitalized children with physician-
diagnosed LRTI from 5 sites in 4 provinces from 2009 to 2012. Using poly-
merase chain reaction (PCR), nasopharyngeal aspirates were tested for 10 
viruses and blood for pneumococcal DNA. Incidence was estimated at 1 site 
with available population denominators.
Results: We enrolled 8723 children aged <5 years with LRTI, including 64% 
<12 months. The case-fatality ratio was 2% (150/8512). HIV prevalence 
among tested children was 12% (705/5964). The overall prevalence of res-
piratory viruses identified was 78% (6517/8393), including 37% rhinovirus, 
26% respiratory syncytial virus (RSV), 7% influenza and 5% human metap-
neumovirus. Four percent (253/6612) tested positive for pneumococcus. The 
annual incidence of LRTI hospitalization ranged from 2530 to 3173/100,000 
population and was highest in infants (8446–10532/100,000). LRTI inci-
dence was 1.1 to 3.0-fold greater in HIV-infected than HIV-uninfected chil-
dren. In multivariable analysis, compared to HIV-uninfected children, HIV-
infected children were more likely to require supplemental-oxygen [odds 
ratio (OR): 1.3, 95% confidence interval (CI): 1.1–1.7)], be hospitalized >7 
days (OR: 3.8, 95% CI: 2.8–5.0) and had a higher case-fatality ratio (OR: 
4.2, 95% CI: 2.6–6.8). In multivariable analysis, HIV-infection (OR: 3.7, 
95% CI: 2.2–6.1), pneumococcal coinfection (OR: 2.4, 95% CI: 1.1–5.6), 
mechanical ventilation (OR: 6.9, 95% CI: 2.7–17.6) and receipt of supple-
mental-oxygen (OR: 27.3, 95% CI: 13.2–55.9) were associated with death.
Conclusions: HIV-infection was associated with an increased risk of LRTI 
hospitalization and death. A viral pathogen, commonly RSV, was identified 
in a high proportion of LRTI cases.
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In 2010, an estimated 1.4 million children died due to acute lower respiratory tract infections (LRTI) and an estimated 11.9 million 
were hospitalized1 H,2IV infection is associated with increased sever-
ity of LRTI and higher case-fatality ratiosT3–5he relative contribu-
tion of viral and bacterial etiologies to the syndrome of LRTI also 
varies by HIV status6 D,7ata from Europe and North America suggest 
that even in the presence of widespread availability of highly active 
antiretroviral therapy (HAART), the incidence of LRTI remains 
elevated in HIV-infected children8,9
There are limited data on the burden, etiology and epide-
miology of LRTI in HIV-infected and HIV-uninfected children in 
sub-Saharan Africa in the era of HAART availability. In South 
Africa among children aged <5 years in 2011, the estimated HIV 
prevalence was 4% and coverage with HAART was approximately 
26%10Haemophilus influenzae type b conjugate vaccine was intro-
duced into the South African immunization program in 1999 and 
the pneumococcal conjugate vaccine (PCV) in 2009A11s bacte-
rial etiologies decline due to vaccination, respiratory viral causes 
of LRTI may gain greater prominence. We aimed to describe the 
incidence, etiology and factors associated with death among HIV-
infected and HIV-uninfected children aged <5 years hospitalized 
with LRTI in South Africa from 2009 through 2012.
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MATERIALS AND METHODS
Description of the Surveillance Program
From February 2009, active, prospective, hospital-based 
surveillance [the Severe Acute Respiratory Illness (SARI) pro-
gram] was implemented in 3 of the 9 provinces of South Africa 
[Chris Hani-Baragwanath Academic Hospital (CHBAH) in an 
urban area of Gauteng Province, Edendale Hospital in a periurban 
area of KwaZulu-Natal Province and Matikwana and Mapulaneng 
Hospitals in a rural area of Mpumalanga Province]. In June 2010, 
an additional surveillance site was introduced at Klerksdorp Hospi-
tal in a periurban area of the Northwest Province12
Case Definition
A case of hospitalized-LRTI was defined as a hospitalized 
child with <7 days symptom duration meeting age-appropriate clin-
ical case definitions (aged 2 days through <3 months of age with 
physician diagnosis of LRTI, including bronchitis, bronchiolitis, 
pneumonia and/or pleural effusion).
Study Procedures
All patients admitted from Monday through Friday were eli-
gible. The total number of children admitted meeting study case 
definitions and numbers enrolled were documented for the entire 
study-period. Study staff completed case report forms until dis-
charge and collected nasopharyngeal aspirates and blood speci-
mens. All decisions on medical-care, including mechanical ventila-
tion and other investigations such as blood bacteria culture, testing 
for Mycobacterium tuberculosis and CD4+ T-lymphocyte counts 
was undertaken at the discretion of the attending-physician. At 
CHBAH, children with LRTI but without World Health Organiza-
tion signs of severe LRTI and who do not require supplemental-
oxygen treatment may be admitted to a short stay ward for 1–2 
days, following which they are either discharged or admitted to 
the general pediatric wards. Children in the short stay wards were 
included. Data in case report forms were reviewed regularly to 
identify inconsistencies and regular site visits conducted to ensure 
adherence to study procedures.
Evaluation of HIV Sero-status
HIV-infection status was determined based on testing under-
taken as part of standard-of-careo13r through anonymized linked 
dried blood spot specimen testing by HIV PCR for children aged 
<18 months and by enzyme-linked immunosorbent assay for indi-
viduals aged ≥18 months. CD4+ T-cell counts were determined 
by flow cytometryP14atients were categorized into 2 immunosup-
pression categories such as (1) severe immunosuppression (CD4+ 
T-lymphocytes <25% among infants, CD4+ <20% among 12–35 
months children or CD4+ <15% among those 36–59 months age) 
or (2) mild or no immunosuppression15
Laboratory Methods
Nasopharyngeal aspirates were immersed in viral trans-
port medium at 4–8°C and transported to the National Institute for 
Communicable Diseases (NICD) within 72 hours of collection. 
Specimens were tested by multiplex real-time reverse-transcription 
PCR assay for 10 respiratory viruses including influenza A and B 
viruses, parainfluenza virus I-III (PIV), respiratory syncytial virus 
(RSV), enterovirus, human metapneumovirus (hMPV), adenovi-
rus and human rhinovirus (hRV)O16wing to challenges with avail-
ability of reagents, we did not test for adenovirus from August to 
October 2009. Streptococcus pneumoniae was identified by quan-
titative real-time PCR detecting the lytA gene from whole blood 
specimens17
Calculation of Incidence
Incidence estimates were calculated for Soweto (CHBAH) 
for which population denominator data were available. This hospi-
tal is the only public hospital serving a community of about 120,000 
children aged <5 years in 2012 among whom <10% have private 
medical insurance. Consequently, many of individuals requiring 
hospitalization from this community are admitted to CHBAH. We 
estimated the incidence of hospitalizations per 100,000 individuals 
using the number of LRTI hospitalizations, adjusting for nonenroll-
ment (refusal to participate and nonenrollment during weekends) 
by age groups and HIV status divided by the mid-year total popula-
tion estimatef18or each year, multiplied by 100,000. HIV prevalence 
in the study population was estimated from the projections of the 
Actuarial Society of South Africa AIDS and Demographic mod-
elT10hese estimates have been validated by comparison with other 
estimates and compare favorably with estimates from population-
based HIV prevalence studiesW19e assumed that the HIV preva-
lence by age group among children not tested for HIV was the same 
as those tested. Confidence intervals for incidence estimates were 
calculated using the Poisson distribution. Age-specific and overall 
age-adjusted risk of hospitalization in HIV-infected and HIV-unin-
fected persons was determined using log-binomial regression. To 
explore the possible effect of missing data on estimates of HIV-
specific incidence, a sensitivity analysis was conducted in which 
all cases not tested for HIV were assumed to be HIV-uninfected.
Analysis of Factors Associated With HIV Infection 
and Death
Univariate and multivariable analyses were performed 
with Stata version 12 (StataCorp Limited, College Station, TX). 
To identify factors associated with HIV status and death, we 
implemented multivariable logistic regression models, starting 
with all variables that were significant at P < 0.1 on univariate 
analysis, and dropping nonsignificant factors with stepwise back-
ward selection. All 2-way interactions were evaluated. Two-sided 
P-values <0.05 were considered significant throughout. For each 
univariate analysis, we used all available case information. In the 
multivariable model, patients with missing data for included vari-
ables were dropped from the model. The Hosmer–Lemeshow test 
was used to evaluate the fit of the model to the data; a P > 0.40 is 
considered a good fit of the model to the data. Age group, dura-
tion of hospitalization and year were defined as categorical vari-
ables with multiple levels. All other variables were defined as the 
presence or absence of the attribute excluding missing data. To 
explore possible bias, patients tested for HIV were compared with 
those not tested.
Ethical Considerations
The protocol was approved by the Research Ethics Commit-
tees of the Universities of the Witwatersrand and KwaZulu-Natal. 
This surveillance was deemed nonresearch by the US CDC.
RESULTS
Demographic and Clinical Characteristics
From February 2009 through December 2012, 13,815 
children <5 years of age fulfilling the LRTI case definition were 
screened for study enrollment, of whom 8723 (63%) were enrolled. 
The most common reasons for nonenrollment were study refusal 
(n = 1209, 24%) or unavailability of a legal guardian (n = 1452, 
29%). Of the children enrolled, 64% (5603) were <12 months age, 
and 69% (6024) were enrolled at CHBAH (see Table, Supplemental 
Digital Content 1, http://links.lww.com/INF/B963).
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HIV infection status was determined in 5964 (68%) enrolled 
children. The proportion of children with available HIV results 
increased from 48% in 2009 to 77% in 2012 (P < 0.001). The over-
all HIV prevalence was 12% (705/5964) and varied by age group: 
10% (249/2565) in those <6 months, 13% (163/1290) in 6–11 
months, 10% (125/1201) in 12–23 months and 19% (168/908) in 
24–59 months (P < 0.001). HIV prevalence varied by hospital: 8% 
(322/3893) at CHBAH, 23% (206/906) at Matikwana and Mapu-
laneng, 14% (118/850) at Edendale and 19% (59/315) at Klerks-
dorp (P < 0.001). At CHBAH, the HIV prevalence among children 
admitted to the short stay ward was 5% (97/1965) compared with 
12% (225/1928) among those admitted to the general pediatric 
wards (P < 0.001).
Only 2% of children reported an underlying medical con-
dition other than HIV-infection (see Table, Supplemental Digital 
Content 1, http://links.lww.com/INF/B963). The case-fatality 
ratio was 2% (150/8512) and 1% (109/8634) were admitted to 
the intensive care unit. Supplemental-oxygen was administered to 
35% (3042/8637) of children (63%, 277/437 at Klerksdorp; 62%, 
661/1062 at Edendale; 21%, 246/1181 at Matikwana and Mapu-
laneng; 59%, 1746/2932 in the CHBAH general pediatric wards and 
4%, 115/3025 at the CHBAH short stay ward). Data on presence or 
absence of World Health Organisation criteria for clinical severity 
of pneumoniw20ere only available for 44% (3841/8723) of children, 
of whom 23% (900/3841) would be classified as having pneumo-
nia, 23% (894/3841) severe pneumonia and 53% (2047/3841) very 
severe pneumonia. All children were eligible to receive H. influen-
zae type b conjugate vaccine and 5292 to receive PCV. Coverage 
of the primary schedule of H. influenzae type b conjugate vaccine 
was 78% (4477/5719) and PCV was 46% (1745/3765) among eli-
gible children with available data. Only 6 patients reported having 
received the influenza vaccine.
Incidence of Hospitalization in HIV-infected and 
HIV-uninfected Patients
The annual incidence per 100,000 population of LRTI hos-
pitalization among children <5 years at CHBAH ranged from 2530 
to 3173, being highest in infants (annual range: 8446–10,532; 
Table 1). In addition, the incidence per 100,000 population was 
higher in children <4 months age (15,573–21,752) than those 
aged 4–11 months (5424–6792). Among children <4 months age, 
the incidence per 100,000 population was higher in HIV-infected 
(27,336–49,966) than HIV-uninfected children (15,044–21,565). 
Similarly in children aged 4–11 months, the incidence per 100,000 
population was higher in HIV-infected (8628–34,152) than HIV-
uninfected children (5105–6730).
HIV-infected children had up to 3-fold greater incidence 
of LRTI compared with uninfected children, although the relative 
risk of hospitalization among HIV-infected individuals decreased 
in later years (Table 1). On sensitivity analysis, assuming that all 
patients not tested for HIV were HIV-uninfected, the trend toward 
a higher incidence of LRTI hospitalizations in HIV-infected com-
pared with uninfected children remained in most age groups and 
most years, but relative risks were lower in more recent years.
Etiologic Agents Identified
Overall, 78% of LRTI episodes was associated with a viral 
infection, including 37% for hRV, 26% for RSV, 26% for adenovi-
rus, 10% for enterovirus and other individual viruses in <10% of 
children (see Table, Supplemental Digital Content 1, http://links.
lww.com/INF/B963). Thirty-three percent (2893/8723) of patients 
had sterile site specimens (2890 blood culture, 2 pleural fluid cul-
ture and 1 blood and pleural fluid culture) submitted for bacterial 
culture. Two percent (75/3196) of patients had a positive bacterial 
culture (see Table, Supplemental Digital Content 1, http://links.
lww.com/INF/B963). Only 37 patients had laboratory-confirmed 
tuberculosis. Four percent (253/6612) of children had pneumococ-
cal infection. Among patients testing positive for pneumococcus, 
76% (187/245) also tested positive for at least 1 respiratory virus, 
similar to the percent testing positive for respiratory viruses among 
pneumococcus-negative patients (76%, 4703/6156). The only virus 
with a significantly different prevalence among pneumococcal-pos-
itive compared with pneumococcal-negative children was influenza 
(13%, 31/245 detection among pneumococcus-positive vs. 7%, 
432/6157 among pneumococcus-negative children, P = 0.001). 
Patients with very severe pneumonia were more likely to test posi-
tive for influenza [6% (48/859) vs. 6% (51/862) vs. 8% (156/1969) 
in pneumonia, severe and very severe pneumonia respectively, P = 
0.03]. There was no association between pneumonia severity and 
any other pathogen tested.
When the proportion of patients testing positive for different 
pathogens was analyzed by age group, the prevalence of infection 
increased with increasing age for influenza, adenovirus, enterovi-
rus, rhinovirus and pneumococcus, while RSV was most common 
in the 0–3 month age group (Table 2). The proportion of patients 
testing positive for individual or any respiratory viruses did not dif-
fer by pneumococcal vaccination status (results not shown). LRTI 
cases were enrolled throughout the year with peaks in late sum-
mer and autumn concomitant with RSV circulation and winter and 
spring associated with influenza circulation (Fig. 1).
Characteristics of HIV-infected Children and 
Factors Associated With HIV Infection
Compared to children without HIV infection, using mul-
tivariable analysis controlling for year and hospital, HIV-infected 
children were more likely to be in the older 24–59 month age group, 
have symptoms ≥2 days before admission, require supplementary-
oxygen, be hospitalized for longer duration and to die (see Table, 
Supplemental Digital Content 1, http://links.lww.com/INF/B963). 
In contrast, they were less likely to be infected with RSV or hMPV.
Only 25% (174/705) of HIV-infected patients had available 
CD4+ T-lymphocyte data, of whom 64% had severe immunosup-
pressionF15orty-four percent (96/217) of those with available data 
reported currently receiving HAART and 30% (207/690) reported 
receiving prophylaxis with trimethoprim–sulfamethoxazole.
Factors Associated With In-hospital Mortality 
Among Children Hospitalized With LRTI
The unadjusted case-fatality ratio was greater among HIV-
infected (47/695, 7%) compared with HIV-uninfected (46/5240, 1%) 
children (see Table, Supplemental Digital Content 2, http://links.lww.
com/INF/B964). On multivariable analysis, controlling for year and 
site, HIV-positivity, pneumococcal infection, receipt of mechanical 
ventilation and receipt of supplementary-oxygen were independent 
risk indicators associated with death, while case-fatality ratio was 
lower in children who tested RSV-positive (see Table, Supplemental 
Digital Content 2, http://links.lww.com/INF/B964). The case-fatality 
ratio was not significantly different between patients with (8%, 9/112) 
and without (3%, 2/61) severe immunosuppression, (P = 0.221) or 
patients receiving (3%, 3/95) and not receiving (8%, 9/118) HAART 
(P = 0.160) although numbers were small.
DISCUSSION
HIV-infected children have an elevated incidence of LRTI 
hospitalization, duration of hospitalization and in-hospital case-
fatality ratio compared with HIV-uninfected children in South 
Africa. This indicates that underlying HIV-infection remains a 
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major risk factor for pneumonia morbidity and mortality in settings 
such as ours, even following HAART availability. Of the respiratory 
viruses with a likely pathogenic role, RSV was identified in more 
than 25% of children, particularly in infants, and influenza was iden-
tified in 7% of children. While pneumococcus was not as commonly 
identified (4% of cases), likely related to lower sensitivity of avail-
able diagnostic assays for pneumococcal pneumonia, infection with 
pneumococcus was an independent risk factor for death.
The overall incidence of hospitalization per 100,000 
population for LRTI in Soweto among children <5 years of age 
(~2500–3000) was similar to that described from Africa in a recent 
systematic review of global pneumonia burden (~2260, 95% CI: 
1530–3340)W2e observed the highest incidence in those aged <12 
months (~8000–11,000/100,000 population), where incidences 
were slightly higher than other estimates for Africa (~5080/100,000 
population, 95% CI: 3360–7690/100,000) but similar to those from 
some studies from middle-income countries2,21,22
Pneumonia is the commonest reason for hospitalization 
among African HIV-infected childrenI6n our study, HIV-infected chil-
dren experienced an elevated incidence of hospitalization compared 
with HIV-uninfected children but this excess risk decreased over the 
study period from 3.7 (95% CI: 3.4–4.0) in 2009 to 1.8 (95% CI: 
1.6–2.1) in 2012, possibly related to more widespread availability of 
early HAART over this period23 S,24tudies have shown that HAART 
availability is associated with a reduction in pneumonia incidence in 
HIV-infected children, albeit HIV-infected children on HAART still 
have a higher incidence of pneumonia3,8 W,9e found that HIV-infected 
children experienced a 4 times increased risk of death compared with 
HIV-uninfected children once hospitalized. This is similar to several 
other studies which reported case-fatality ratios 3–6 times greater 
in HIV-infected children6,7,25 T,26he overall case-fatality ratios among 
HIV-infected children in our study are, however, lower than has pre-
viously been described in HIV-infected children from South Africa, 
possibly related to more widespread HAART availability.
TABLE 1. Incidence of Acute LRTI Hospitalizations per 100,000 Population by Year and HIV Status Among Children 
<5 Years in Soweto, as Measured at Chris Hani-Baragwanath Hospital, South Africa
Year
Age Group  
(months)
IR 
(95% CI)
All Patients
IR
(95% CI)
HIV Infected
IR
(95% CI)
HIV Uninfected
RR
(95% CI)
HIV Infected vs.  
HIV Uninfected
RR
(95% CI)
HIV Infected vs. HIV 
Uninfected  
Sensitivity Analysis†
2009 <12 9965 (9572–10,373) 36,745 (32,970–40,747) 8857 (8480–9251) 4.1 (3.7–4.6) 2 (1.7–2.3)
12–23 3189 (2971–3420) 5753 (4486–7246) 3054 (2835–3287) 1.9 (1.5–2.4) 0.8 (0.5–1.1)
24–59 978 (909–1052) 3522 (2947–4206) 850 (783–920) 4.2 (3.4–5.0) 1.5 (1.1–2.0)
All 3173 (3075–3275) 9502 (8725–9251) 2862 (2767–2961) 3.7 (3.4–4.0) 1.6 (1.5–1.8)
2010 <12 8861 (8478–9258) 23,038 (19,723–26,701) 8372 (7994–8765) 2.7 (2.3–3.2) 1.7 (1.4–2.1)
12–23 2645 (2443–2865) 5508 (4218–7052) 2500 (2295–2715) 2.2 (1.7–2.9) 1.4 (1.0–1.9)
24–59 563 (510–621) 1508 (1137–1997) 516 (465–574) 2.9 (2.2–3.9) 1.5 (1.0–2.2)
All 2561 (2471–2655) 5431 (4826–6101) 2427 (2337–2520) 2.7 (2.4–3.0) 1.6 (1.4–1.9)
2011 <12 10,532 (10,123–10,952) 13,309 (10,890–16,181) 10,438 (10,024–10,863) 1.3 (1.0–1.5) 0.9 (0.7–1.2)
12–23 3009 (2796–3239) 3375 (2299–4691) 2993 (2774–3225) 1.1 (0.8–1.6) 0.9 (0.6–1.4)
24–59 494 (444–548) 1146 (813–1577) 463 (414–516) 2.5 (1.7–3.5) 1.8 (1.2–2.6)
All 2972 (2876–3072) 3434 (2943–3984) 2952 (2853–3052) 1.4 (1.2–1.6) 1.0 (0.9–1.2)
2012 <12 8446 (8083–8821) 16,893 (14,088–20,021) 8167 (7805–8543) 2.1 (1.7–2.5) 1.5 (1.2–1.8)
12–23 2375 (2186–2579) 2512 (1585–3681) 2370 (2174–2575) 1.1 (0.7–1.6) 0.8 (0.5–1.3)
24–59 618 (563–679) 1150 (817–1614) 595 (538–655) 2 (1.4–2.8) 1.4 (0.9–2.1)
All 2530 (2442–2622) 3936 (3395–4536) 2472 (2382–2564) 1.8 (1.6–2.1) 1.3 (1.1–1.6)
*Significant values at P < 0.05 are in bold.
†Assuming that all patients not tested for HIV are HIV-negative.
IR indicates incidence rate; RR, relative risk.
TABLE 2. Percentage of Patients Testing Positive for Viral and Bacterial Pathogens by Age Group Among Children 
<5 Years Hospitalized With Acute LRTI at 4 Sentinel Surveillance Sites, South Africa, 2009–2012
Age Group
0–3 Months
n/N (%)
4–11 Months
n/N (%)
12–23 Months
n/N (%)
24–59 Months
n/N (%) P*
Influenza 109/2726 (4) 201/2637 (8) 153/1703 (9) 150/1328 (11) <0.001
Adenovirus 298/2558 (12) 646/2448 (26) 600/1559 (38) 517/1234 (42) <0.001
Enterovirus 207/2725 (8) 245/2637 (9) 249/1703 (15) 176/1328 (13) <0.001
Rhinovirus 816/2725 (30) 1027/2637 (39) 677/1703 (40) 595/1328 (45) <0.001
Human metapneumovirus 129/2725 (5) 211/2637 (8) 97/1703 (6) 67/1328 (5) <0.001
Parainfluenzavirus 1 28/2725 (1) 54/2637 (2) 46/1703 (3) 33/1328 (2) <0.001
Parainfluenzavirus 2 21/2725 (1) 42/2637 (2) 27/1703 (2) 26/1328 (2) 0.007
Parainfluenzavirus 3 136/2725 (5) 229/2637 (9) 126/1702 (7) 44/1328 (3) <0.001
Respiratory syncytial virus 897/2725 (33) 717/2637 (27) 374/1703 (22) 228/1328 (17) <0.001
Any respiratory virus 1883/2725 (69) 2146/2637 (81) 1410/1703 (83) 1078/1328 (81) <0.001
>1 Respiratory virus 602/2725 (22) 932/2637 (35) 676/1703 (40) 550/1328 (41) <0.001
Invasive bacterial infection on culture 32/1440 (2) 19/876 (2) 14/499 (3) 13/381 (3) 0.503
Pneumococcal infection** 70/2254 (3) 75/2063 (4) 59/1302 (5) 49/993 (5) 0.037
*For heterogeneity between age groups.
**Detected on lytA PCR or blood culture.
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HRV (37%), RSV (26%) and adenovirus (26%) were the 
most commonly identified respiratory viruses, while influenza 
was identified in 7% of patients, similar to what has been found 
in other studies from Africa using PCR for viral diagnosis22 C,27–
29hallenges remain for the attribution of a causal role for some 
viruses (including hRV, adenovirus and enterovirus), which are 
also identified at high frequency from healthy individuals22,27 R,29SV 
and hMPV (both thought to have a likely pathogenic role) were 
identified less frequently in HIV-infected than HIV-uninfected 
children suggesting that the increased risk of hospitalization due 
A
B
C
FIGURE 1. Number of patients 
enrolled with LRTI and detection rates 
by epidemiologic week and year at 
4 sentinel surveillance sites, South 
Africa, 2009–2011. (A) Influenza, RSV 
and pneumococcal detection rates. 
(B) Enterovirus, rhinovirus and human 
metapneumovirus detection rates. 
(C) Adenovirus and parainfluenza virus 
1, 2 and 3 detection rates.
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to HIV-associated immunosuppression is relatively lower for these 
pathogens than for other etiologies. Previous studies from South 
Africa have shown that while the detection rate for viruses may be 
lower in HIV-infected children, the incidence of hospitalization is 
substantially higher in HIV-infected compared with HIV-uninfected 
children7 C,30hildren with RSV were less likely to die, as has been 
previously describedT22his is likely because the relative contribu-
tion of viral etiologies compared with bacterial etiologies is greater 
for hospitalized pneumonia than among deaths 31high proportion of 
children were coinfected with multiple respiratory viruses (33%), 
as has been described previously, although coinfection was not 
associated with adverse outcome16,29 H,32IV-infected children have 
been described to have an increased risk of polymicrobial infec-
tions due to multiple bacterial, viral and fungal pathogensW3e were 
not able to assess this as we did not systematically test for impor-
tant pathogens in HIV-infected children, particularly tuberculosis, 
Pneumocystis jiroveci and cytomegalovirus.
Blood cultures were performed in less than half of children, 
limiting our ability to comment on the proportion with bacteremic 
pneumonia, but similar to other studies from South Africa, the 
pneumococcus and Staphylococcus aureus were the most common 
bacteria identified. S. pneumoniae is an important cause of pneu-
monia in HIV-infected and HIV-uninfected children25 I,26n our study, 
we identified pneumococcus from 4% of children overall using a 
combination of PCR and blood cultures (performed in a minority of 
patients). These rates are similar to other studies from South Africa 
before PCV introduction which used systematic blood culture col-
lection only25 F,26ailure to observe lower detection rates after PCV 
introduction may be attributed to our diagnostic technique, real-
time PCR, identifying more pneumococcal cases than blood cul-
ture in our settingN33otwithstanding this, additional cases of pneu-
mococcal coinfection may still have been missed34 P,35neumococcal 
DNA in the blood may reflect occult bacteremia in some individu-
alsP36–38atients testing positive for pneumococcus had a high preva-
lence of detection of respiratory viruses although many of these 
may have been bystander virusesI32nfluenza was the only virus to 
be more commonly detected in patients testing positive for pneu-
mococcus. The association between influenza and pneumococcal 
infection has been described previously12,39
Our study had potential limitations. HIV status data was 
only available for approximately 60% of children. If the charac-
teristics of untested children differed from those of tested children 
this may have biased findings; however, we did not find any sig-
nificant differences in epidemiologic characteristics of tested and 
untested patients (results not shown). In addition, for the estimation 
of incidence stratified by HIV status, we conducted a sensitivity 
analysis to explore the scenario if all untested children were HIV-
uninfected. Data on access to HAART and CD4+ T-cell count were 
only available for a limited number of HIV-infected children limit-
ing our ability to comment on the effect of HAART and degree of 
immunocompromise on disease incidence and severity. Incidence 
data were only available for 1 urban site with available denomina-
tor data and thus may not be generalizable to other settings within 
South Africa. We may have underestimated incidence as not all 
cases may have sought care in hospital. Similarly, patients who die 
may be less likely to be enrolled into studies such as ours and this 
may lead to underestimation of case-fatality ratios and potential 
exclusion of most severely ill children 27The denominators for the 
numbers of HIV-infected and HIV-uninfected children each year 
were obtained from the 2008 version of the Actuarial Society of 
South Africa model. Subsequent to the development of this model, 
rates of access to prevention of mother-to-child transmission and 
early HAART among children have been more rapid than expected 
leading to possible overestimation of the numbers of children with 
AIDS in South Africa, which could have led to an underestimation 
of the relative risk of hospitalization in HIV-infected children10 ,24There 
were a large number of statistical analyses conducted on these data 
and corrections were not made for multiple testing.
In conclusion, we have demonstrated a high incidence of 
hospitalization 1 for LRTI amongst children aged <5 years in South 
Africa, particularly in children aged <1 year and HIV-infected 
children. HIV-infected children also experience increased hospi-
talization duration and mortality. RSV was an important cause of 
pneumonia. Vaccines for RSV are currently under development and 
could be expected to have a substantial impact on pneumonia bur-
den if they become available.40 Ongoing reductions in burden of 
pneumococcal pneumonia may be expected following PCV intro-
duction. Influenza was identified in 7% of children and influenza 
vaccination is recommended for children <5 years in South Africa 
but very few children in our study reported being vaccinated.41 
Influenza vaccines are less effective in children <5 years than 
healthy adults and efficacy has not been demonstrated in HIV-
infected children.42 More widespread access to influenza vaccines 
could, however, potentially impact disease burden, particularly if 
newer formulations such as adjuvanted vaccines are shown to be 
safe and effective in our setting. HIV remains a major risk factor 
for LRTI and adverse outcome, and more widespread adherence to 
PMTCT protocols and availability of HAART can be expected to 
have ongoing impact in reducing disease burden.3,6
REFERENCES
 1. Liu L, Johnson HL, Cousens S, et al; Child Health Epidemiology Reference 
Group of WHO and UNICEF. Global, regional, and national causes of child 
mortality: an updated systematic analysis for 2010 with time trends since 
2000. Lancet. 2012;379:2151–2161.
 2. Nair H, Simooes EA, Rudan I, et al. Global and regional burden of hospital 
admissions for severe acute lower respiratory infections in young children 
in 2010: a systematic analysis. Lancet 2013;10–6736.
 3. Gray DM, Zar HJ. Community-acquired pneumonia in HIV-infected chil-
dren: a global perspective. Curr Opin Pulm Med. 2010;16:208–216.
 4. Jaspan HB, Huang LC, Cotton MF, et al. Bacterial disease and antimicrobial 
susceptibility patterns in HIV-infected, hospitalized children: a retrospective 
cohort study. PLoS One. 2008;3:e3260.
 5. McNally LM, Jeena PM, Gajee K, et al. Effect of age, polymicrobial dis-
ease, and maternal HIV status on treatment response and cause of severe 
pneumonia in South African children: a prospective descriptive study. 
Lancet. 2007;369:1440–1451.
 6. Zar HJ, Madhi SA. Childhood pneumonia–progress and challenges. S Afr 
Med J. 2006;96(9, pt 2):890–900.
 7. Madhi SA, Schoub B, Simmank K, et al. Increased burden of respiratory 
viral associated severe lower respiratory tract infections in children infected 
with human immunodeficiency virus type-1. J Pediatr. 2000;137:78–84.
 8. Gona P, Van Dyke RB, Williams PL, et al. Incidence of opportunistic 
and other infections in HIV-infected children in the HAART era. JAMA. 
2006;296:292–300.
 9. Chiappini E, Galli L, Tovo PA, et al. Changing patterns of clinical events 
in perinatally HIV-1-infected children during the era of HAART. AIDS. 
2007;21:1607–1615.
 10. Actuarial Society of South Africa (ASSA). AIDS and Demographic model. 
Available at: http://aids.actuarialsociety.org.za/ASSA2008-Model-3480.htm. 
Accessed August 27, 2014..
 11. Madhi SA, Cohen C, von Gottberg A. Introduction of pneumococcal conju-
gate vaccine into the public immunization program in South Africa: translat-
ing research into policy. Vaccine. 2012;30(suppl 3):C21–C27.
 12. Cohen C, Moyes J, Tempia S, et al. Severe influenza-associated respiratory 
infection in high HIV prevalence setting, South Africa, 2009-2011. Emerg 
Infect Dis. 2013;19:1766–1774.
 13. Singh E, Cohen C, Govender N, Meiring S. A description of HIV testing 
strategies at 21 laboratories in South Africa. Commun Dis Surveill Bull. 
2008;6:16–17.
Cohen et al The Pediatric Infectious Disease Journal • Volume 34, Number 1, January 2015
72 | www.pidj.com © 2014 Lippincott Williams & Wilkins
 14. Glencross D, Scott LE, Jani IV, et al. CD45-assisted PanLeucogating for 
accurate, cost-effective dual-platform CD4+ T-cell enumeration. Cytometry. 
2002;50:69–77.
 15. World Health Organisation HIV/AIDS Programme. WHO Case Definitions 
of HIV for Surveillance and Revised Clinical Staging and Immunologic 
Classification of HIV-related Disease in Adults and Children. Geneva, 
Switzerland: World Health Organisation; 2007.
 16. Pretorius MA, Madhi SA, Cohen C, et al. Respiratory viral coinfections 
identified by a 10-plex real-time reverse-transcription polymerase chain 
reaction assay in patients hospitalized with severe acute respiratory illness–
South Africa, 2009-2010. J Infect Dis. 2012;206(suppl 1):S159–S165.
 17. Carvalho MG, Tondella ML, McCaustland K, et al. Evaluation and improve-
ment of real-time PCR assays targeting lytA, ply, and psaA genes for detec-
tion of pneumococcal DNA. J Clin Microbiol. 2007;45:2460–2466.
 18. Statistics South Africa. STATSSA, Mid-year Population Estimates 2003–
2008. Pretoria, South Africa: Statistics South Africa; 2008.
 19. Shisana, O, Rehle T, Simbayi LC, et al; the SABSSM III Implementation 
Team. South African National HIV Prevalence, Incidence, Behaviour and 
Communication Survey, 2008: A Turning Tide Among Teenagers? Cape 
Town, South Africa: HSRC Press; 2009.
 20. World Health Organisation. Integrated management of childhood illness. 
Handbook IMCI. Geneva, Switzerland: World Health Organisation; 2000.
 21. Olsen SJ, Laosiritaworn Y, Siasiriwattana S, et al. The incidence of pneumo-
nia in rural Thailand. Int J Infect Dis. 2006;10:439–445.
 22. Berkley JA, Munywoki P, Ngama M, et al. Viral etiology of severe pneumo-
nia among Kenyan infants and children. JAMA. 2010;303:2051–2057.
 23. Johnson LF, Davies MA, Moultrie H, et al. The effect of early initiation 
of antiretroviral treatment in infants on pediatric AIDS mortality in South 
Africa: a model-based analysis. Pediatr Infect Dis J. 2012;31:474–480.
 24. Johnson LF. Access to antiretroviral treatment in South Africa, 2004–2011. 
South Afr J HIV Med. 2012;13:22–27.
 25. Madhi SA, Petersen K, Madhi A, et al. Increased disease burden and anti-
biotic resistance of bacteria causing severe community-acquired lower res-
piratory tract infections in human immunodeficiency virus type 1-infected 
children. Clin Infect Dis. 2000;31:170–176.
 26. Zar HJ, Hanslo D, Tannenbaum E, et al. Aetiology and outcome of pneu-
monia in human immunodeficiency virus-infected children hospitalized in 
South Africa. Acta Paediatr. 2001;90:119–125.
 27. Hammitt LL, Kazungu S, Morpeth SC, et al. A preliminary study of pneu-
monia etiology among hospitalized children in Kenya. Clin Infect Dis. 
2012;54(suppl 2):S190–S199.
 28. O’Callaghan-Gordo C, Díez-Padrisa N, Abacassamo F, et al. Viral acute 
respiratory infections among infants visited in a rural hospital of southern 
Mozambique. Trop Med Int Health. 2011;16:1054–1060.
 29. Feikin DR, Njenga MK, Bigogo G, et al. Viral and bacterial causes of severe 
acute respiratory illness among children aged less than 5 years in a high 
malaria prevalence area of western Kenya, 2007-2010. Pediatr Infect Dis J. 
2013;32:e14–e19.
 30. Moyes J, Cohen C, Pretorius M, et al. Epidemiology of respiratory syncy-
tial virus-associated acute lower respiratory tract infection hospitalizations 
among HIV-infected and HIV-uninfected South African children, 2010–
2011. J Infect Dis. 2013;208(suppl 3):S217–S226.
 31. Rudan I, O’Brien KL, Nair H, et al. Epidemiology and etiology of childhood 
pneumonia in 2010: estimates of incidence, severe morbidity, mortality, 
underlying risk factors and causative pathogens for 192 countries. J Glob 
Health. 2013;3:10401.
 32. Ruuskanen O, Lahti E, Jennings LC, et al. Viral pneumonia. Lancet. 
2011;377:1264–1275.
 33. Wolter N, Cohen C, Tempia S, et al. HIV and influenza are associated with 
increased blood pneumococcal load, South Africa, 2009–2011. J Infect Dis. 
2013;209(1):56–65.
 34. Madhi SA, Kuwanda L, Cutland C, et al. The impact of a 9-valent pneu-
mococcal conjugate vaccine on the public health burden of pneumonia in 
HIV-infected and -uninfected children. Clin Infect Dis. 2005;40:1511–1518.
 35. Resti M, Moriondo M, Cortimiglia M, et al; Italian Group for the Study 
of Invasive Pneumococcal Disease. Community‐acquired bacteremic pneu-
mococcal pneumonia in children: diagnosis and serotyping by real‐time 
polymerase chain reaction using blood samples. Clin Infect Dis. 2010;51: 
1042–1049.
 36. Azzari C, Moriondo M, Indolfi G, et al. Molecular detection methods and 
serotyping performed directly on clinical samples improve diagnostic sen-
sitivity and reveal increased incidence of invasive disease by Streptococcus 
pneumoniae in Italian children. J Med Microbiol. 2008;57(pt 10):1205–1212.
 37. Rouphael N, Steyn S, Bangert M, et al. Use of 2 pneumococcal common 
protein real-time polymerase chain reaction assays in healthy children 
colonized with Streptococcus pneumoniae. Diagn Microbiol Infect Dis. 
2011;70:452–454.
 38. Dagan R, Shriker O, Hazan I, et al. Prospective study to determine clinical 
relevance of detection of pneumococcal DNA in sera of children by PCR. J 
Clin Microbiol. 1998;36:669–673.
 39. Madhi SA, Klugman KP; Vaccine Trialist Group. A role for Streptococcus 
pneumoniae in virus-associated pneumonia. Nat Med. 2004;10:811–813.
 40. Haynes LN. Progress and challenges in RSV prophylaxis and vaccine devel-
opment. J Infect Dis. 2013;208:S177–S183.
 41. The National Institute for Communicable Diseases (NICD) of the National 
Health Laboratory Service (NHLS). Healthcare Workers Handbook of 
Influenza. Johannesburg, South Africa: National Institute for Communicable 
Diseases; 2012.
 42. Madhi SA, Dittmer S, Kuwanda L, et al. Efficacy and immunogenicity of 
influenza vaccine in HIV-infected children: a randomized, double-blind, pla-
cebo controlled trial. AIDS. 2013;27:369–379.
